In 106 adults with short bowel syndrome and intestinal failure, glepaglutide twice weekly cut weekly parenteral support volume more than placebo at 24 weeks (mean −5.13 vs −2.85 L/wk; P=.0039); once-weekly dosing showed no significant benefit.
RCTn = 106
Jeppesen et al. Glepaglutide, a Long-Acting Glucagon-like Peptide-2 Analogue, Reduces Parenteral Support in Patients With Short Bowel Syndrome: A Phase 3 Randomized Controlled Trial